NFL BIOSCIENCES: Decision to approve the issuing of its patent in South Korea
12 May 2022 - 2:15AM
NFL BIOSCIENCES: Decision to approve the issuing of its patent in
South Korea
NFL BIOSCIENCES: Decision to approve the issuing of its
patent in South Korea
NFL BIOSCIENCES (Euronext Growth Paris –
FR0014003XT0 – ALNFL), a biopharmaceutical company developing
botanical drugs for the treatment of addictions, is announcing that
it has received approval from the South Korean intellectual
property office for issuing its patent (South Korean application
no.10-2018-7032224) for NFL-101, a nicotine-free botanical drug
candidate comprising natural proteins extracted from tobacco
leaves, focused primarily on smoking cessation. This patent will
protect the innovation that NFL-101 is based on through to 2036 in
South Korea.
NFL Biosciences has adopted a knowledge
management and protection strategy that led it to submit two patent
families granting it exclusive rights to its drug candidate
NFL-101. This product patent, initially registered and approved in
France, concerns an “aqueous extract of tobacco leaves and its use
for the treatment of dependence”. The innovation that NFL-101 is
based on is therefore protected through to 2036 in France, the
United States, China and now South Korea. National registration
applications are also in the review phase in the following regions
and countries: Japan, Canada, Australia, Brazil, India, Indonesia,
Israel, Mexico, Philippines, Eurasia, Saudi Arabia, United Arab
Emirates and Nigeria.
South Korea has more than nine million daily
smokers1.
“We are continuing to move forward with our
patent registration schedule in line with our global strategy.
Following China, the securing of this patent in South Korea will
further strengthen the protection of the innovation behind NFL-101.
We are continuing to build our coverage across Asia, a key region
in the fight against smoking and a major market for NFL Biosciences
and its drug candidate”, confirms Bruno Lafont, Chief Operating
Officer and co-founder of NFL Biosciences.
About
NFL Biosciences
NFL Biosciences is a biopharmaceutical company
based in the Montpellier area which develops botanical drug
candidates for the treatment of addictions. NFL Biosciences'
ambition is to bring new, natural, safer and more effective
therapeutic solutions to the entire world population, including
low- and middle-income countries. Its most advanced product, called
NFL-101, is a standardized, nicotine-free tobacco leaf extract
protected by two patent families. NFL Biosciences intends to offer
smokers who want to quit a natural, safe, easy-to-administer and
personalized alternative. NFL Biosciences is also developing
NFL-301, a natural drug candidate for the reduction of alcohol
consumption and has a drug development project for the treatment of
cannabis use disorders.
The shares of NFL Biosciences are listed on
Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at
www.nflbiosciences.com
Contacts
Bruno Lafont – info@nflbiosciences.com - 04 11
93 76 67 Agence
Calyptus – nflbio@calyptus.net - 01 53 65 68 68
1 Source: OECD.org (2019)
- 20220511_NFLBioscience_issuing_patent_South_Korea_EN_vDEF
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
From Jul 2024 to Aug 2024
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
From Aug 2023 to Aug 2024